The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative chemotherapy versus preoperative chemoradiotherapy in resectable esophageal cancer: A real-world analysis.
 
Sebawe Syaj
No Relationships to Disclose
 
Leen Alkuttob
No Relationships to Disclose
 
Abdul Qahar Yasinzai
No Relationships to Disclose
 
Arjun Pennathur
No Relationships to Disclose
 
Evan Alicuben
No Relationships to Disclose
 
Joel Greenberger
No Relationships to Disclose
 
Susannah Ellsworth
No Relationships to Disclose
 
Neal Mccall
No Relationships to Disclose
 
James Luketich
No Relationships to Disclose
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline; Guardant Health; Seagen
Speakers' Bureau - Amgen; Pfizer
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem Therapeutics; Autem therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Regeneron; Replimune; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Phanes Therapeutics (Inst); Replimune (Inst)